A Predictive Model of Rectal Tumor Response to Preoperative Radiotherapy Using Classification and Regression Tree Methods

Purpose: The ability to predict rectal tumor response to preoperative radiotherapy before treatment would significantly impact patient selection. In this study, classification and regression tree (CART) methods were used to model tumor response to preoperative conformal high-dose rate brachytherapy by assessing the predictive value of vascular endothelial growth factor (VEGF), Bcl-2, p21, p53, and APAF-1. Experimental Design: Immunohistochemistry was used to detect VEGF, Bcl-2, p21, p53, and APAF-1 from 62 pretreatment rectal tumor biopsies. Scores were assigned as percentages of positive tumor cell staining and were used in CART analysis to identify the proteins that best predicted response to radiotherapy. Ten-fold cross-validation was used to prevent overfitting and multiple cross-validation experiments were run to estimate the prediction error. Results: Postoperative pathologic evaluation of the irradiated tumor bed revealed 43 responsive tumors [20 with complete response (T0) and 23 with partial response] and 19 nonresponsive tumors. The optimal tree resulting from CART analysis had five terminal nodes with a misclassification rate of 18%. Of the five proteins selected for their predictive value, VEGF and Bcl-2 contributed most to the classification of responsive and nonresponsive tumors. All 10 tumors with no VEGF were completely responsive (T0) to radiotherapy; 85% of those with VEGF and negative for Bcl-2 were responsive to therapy. Conclusions: VEGF and Bcl-2 status in pretreatment rectal tumor biopsies may be predictive of response to preoperative high-dose rate brachytherapy.

[1]  C. Reinhold,et al.  Conformal Preoperative Endorectal Brachytherapy Treatment for Locally Advanced Rectal Cancer , 2002, Diseases of the colon and rectum.

[2]  K. Maeda,et al.  Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis , 1997, International journal of cancer.

[3]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[4]  J. Harmey,et al.  Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[5]  H. Grönberg,et al.  A Systematic Overview of Radiation Therapy Effects in Rectal Cancer , 2003, Acta oncologica.

[6]  T. Hwang,et al.  Differential, stage‐dependent expression of Hsp70, Hsp110 and Bcl‐2 in colorectal cancer , 2003, Journal of gastroenterology and hepatology.

[7]  S. Stryker,et al.  Molecular markers and prediction of response to chemoradiation in rectal cancer. , 2001, Oncology reports.

[8]  S. Leung,et al.  Vascular endothelial growth factor is up‐regulated in the early pre‐malignant stage of colorectal tumour progression , 1999, International journal of cancer.

[9]  R. Broll,et al.  Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer? , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  F. Ciardiello,et al.  Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma , 2004, Cancer.

[11]  S. Baldus,et al.  Prognostic impact of p21/waf1/cip1 in colorectal cancer , 2000, International journal of cancer.

[12]  G. Thomas,et al.  Prognostic value of P53 mutations in rectal carcinoma , 2002, International journal of cancer.

[13]  P. Farmer,et al.  The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.

[14]  S. Yun,et al.  p53, BCL-2, and Ki-67 Expression According to Tumor Response After Concurrent Chemoradiotherapy for Advanced Rectal Cancer , 2001, Annals of Surgical Oncology.

[15]  A Hartz,et al.  The inexact use of Fisher's Exact Test in six major medical journals. , 1989, JAMA.

[16]  S. Arii,et al.  Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma , 2000, Cancer.

[17]  B. Gastman,et al.  Apoptosis and its clinical impact , 2001, Head & neck.

[18]  T. Aoki,et al.  Induction of apoptosis by p53, bax, bcl-2, and p21 expressed in colorectal cancer , 2003, International Journal of Clinical Oncology.

[19]  S. Omatu,et al.  Pattern recognition with neural networks , 2000, IGARSS 2000. IEEE 2000 International Geoscience and Remote Sensing Symposium. Taking the Pulse of the Planet: The Role of Remote Sensing in Managing the Environment. Proceedings (Cat. No.00CH37120).

[20]  R. Pötter,et al.  TP53 Genotype but Not p53 Immunohistochemical Result Predicts Response to Preoperative Short-Term Radiotherapy in Rectal Cancer , 2002, Annals of surgery.

[21]  D. Bouchier-Hayes,et al.  Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells , 2001, British Journal of Cancer.

[22]  D. Rothenberger,et al.  Molecular prognostic factors in rectal cancer treated by radiation and surgery , 2000, Diseases of the colon and rectum.

[23]  R. Salgado,et al.  Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma , 2004, Cancer.

[24]  M. Nozue,et al.  Over-expression of vascular endothelial growth factor after preoperative radiation therapy for rectal cancer. , 2001, Oncology reports.

[25]  C. Vagianos,et al.  bcl-2/bax Ratio as a Predictive Marker for Therapeutic Response to Radiotherapy in Patients With Rectal Cancer , 2001, Applied immunohistochemistry & molecular morphology : AIMM.

[26]  R. Bristow,et al.  The p53 protein family and radiation sensitivity: Yes or no? , 2004, Cancer and Metastasis Reviews.

[27]  M. Gregor,et al.  Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma , 1999, Cancer.

[28]  H. McLeod,et al.  Analysis of key cell‐cycle checkpoint proteins in colorectal tumours , 2002, The Journal of pathology.

[29]  G. Viale,et al.  p21WAF1/CIP1 expression in colorectal carcinoma correlates with advanced disease stage and p53 mutations , 1999, The Journal of pathology.

[30]  H. Nielsen,et al.  Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma , 2000 .

[31]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[32]  R. D'Amato,et al.  Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. , 2001, Journal of the National Cancer Institute.

[33]  P. Adeleine,et al.  Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. Chung,et al.  Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis , 2000, Oncogene.

[35]  R. Newcombe,et al.  Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? , 2004, British Journal of Cancer.

[36]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[37]  F. Ciardiello,et al.  Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas , 2004, Clinical Cancer Research.

[38]  J. Liu,et al.  Apoptosome dysfunction in human cancer , 2004, Apoptosis.

[39]  J. Dahm-Daphi p53: Biology and Role for Cellular Radiosensitivity , 2000, Strahlentherapie und Onkologie.

[40]  L. Påhlman,et al.  Local recurrence rate in a randomized multicentre trial of preoperative radiotherapy compared to surgery alone in resectable rectal carcinoma. , 1996 .

[41]  K. Hess,et al.  p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  T. Pawlik,et al.  Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[43]  L Påhlman,et al.  Improved survival with preoperative radiotherapy in resectable rectal cancer. , 1997, The New England journal of medicine.

[44]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[45]  G. Hospers,et al.  Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. , 2004, Anticancer research.

[46]  W. Curran,et al.  Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. , 2004, Anticancer research.

[47]  S. Barni,et al.  An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation , 2002, British Journal of Cancer.